Search - tctmd.com

Displaying 21 - 40 of 96

Sort: Relevancy | Date

Presentation TCT 2017

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

Presenter: Azeem Latib, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

Presenter: Azeem Latib, Manel Sabate

October 31, 2017

Presentation TCT 2017

New Insights From AIDA: Subgroups and Predictors of Adverse Events

Presenter: Azeem Latib, Joanna J. Wykrzykowska

October 31, 2017

Presentation TCT 2017

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Stephan Achenbach, Jacques J. Koolen, Ron Waksman

October 31, 2017

Presentation TCT 2017

ABSORB PSP: Impact of Technique on Early and Late Outcomes Following Coronary Bioresorbable Scaffold Implantation

Presenter: Y. S. Chandrashekhar, David J. Moliterno, Gregg W. Stone

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

TCT 12: Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis Multistudy Registry Results

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

TCT 43: Bioresorbable Scaffold for the Treatment of Calcified Coronary Lesions: IVUS Insights From the ABSORB Japan Trial

Presenter: Ulf Landmesser, Bernhard Witzenbichler, Kozo Okada, MD

October 31, 2017

Presentation TCT 2017

TCT 9: Absorb Bioresorbable Vascular Scaffold vs Everolimus-Eluting Metallic Stent in Small Vessel Disease -A Propensity Matched Analysis of COMPARE II, RAI, and MAASSTAD-ABSORB Prospective Studies

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Alberto Barioli, MD

October 31, 2017

Presentation TCT 2017

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Robert-Jan van Geuns, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

Association Between Scaffold Under-Expansion and Late Lumen Loss After Bioresorbable Scaffold Implantation - IVUS and Angiographic Insights From the ABSORB Japan Trial

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Kozo Okada, MD

October 31, 2017

Presentation TCT 2017

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

Presenter: David P. Faxon, Joseph A. Hill, Ziad A. Ali

October 31, 2017

Presentation TCT 2017

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Gregg W. Stone

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

Presentation TCT 2017

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

Presenter: Tony Das, Thomas Zeller

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Presenter: C. Michael Gibson, Stephan Windecker, Stephan Achenbach

October 30, 2017

Presentation TCT 2017

Lessons from the ABSORB Clinical Program for the Future

Presenter: Gary S. Mintz, Seung-Jung Park, Patrick W. Serruys

October 29, 2017

Advertisement

Featured Lecture: ABSORB Program 3-Year Meta-Analysis and Adjusted PSP Evaluation - Lessons Learned With a First Generation Scaffold

ABSORB II at 4 Years: Clinical Outcomes Beyond the Cusp of Complete Bioresorption

ABSORB in STEMI I: TROFI II 3-Year Clinical Outcomes and Correlations With the 6-Month OCT Findings

New Insights From AIDA: Subgroups and Predictors of Adverse Events

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

ABSORB PSP: Impact of Technique on Early and Late Outcomes Following Coronary Bioresorbable Scaffold Implantation

Long-term Absorb BVS Data Continue to Disappoint

TCT 12: Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis Multistudy Registry Results

TCT 43: Bioresorbable Scaffold for the Treatment of Calcified Coronary Lesions: IVUS Insights From the ABSORB Japan Trial

TCT 9: Absorb Bioresorbable Vascular Scaffold vs Everolimus-Eluting Metallic Stent in Small Vessel Disease -A Propensity Matched Analysis of COMPARE II, RAI, and MAASSTAD-ABSORB Prospective Studies

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Association Between Scaffold Under-Expansion and Late Lumen Loss After Bioresorbable Scaffold Implantation - IVUS and Angiographic Insights From the ABSORB Japan Trial

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Live From Denver: TCT 2017, Day Two

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Lessons from the ABSORB Clinical Program for the Future

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content